Bio test

from Wikipedia, the free encyclopedia
Biotest Aktiengesellschaft

logo
legal form Corporation
ISIN DE0005227201 (common shares), DE0005227235 (preferred shares)
Seat Dreieich , GermanyGermanyGermany 
management
  • Michael Ramroth, CEO and CFO
  • Georg Floß, Chief Operations Officer
  • Rolf Hoffmann, Chairman of the Supervisory Board
Number of employees 1,663 FTEs
sales 419.1 million euros (2019)
Branch Pharmaceutical Industry
Website www.biotest.de
As of March 3, 2020

The Biotest Aktiengesellschaft is a globally active, publicly traded provider of medicines derived from human blood plasma are obtained based in Hesse Dreieich . The company has specialized in the application areas of clinical immunology , hematology as well as intensive care and emergency medicine. Biotest covers all essential elements of the value chain, from preclinical and clinical development to production and global marketing . Among other things, it works on the development of monoclonal antibodies . At the end of 2018, Biotest had over 1,600 employees. Company headquarters and production site is Dreieich.

history

The company was founded in 1946 as Biotest Serum-Institut GmbH in Frankfurt by Carl Adolf Schleussner and his son Hans Schleussner. Based on the findings of Karl Landsteiner , the main research focus was on blood group serology . The first product was the test serum Anti-D (to determine the Rhesus factor ). Blood transfusions with incompatible blood could now be avoided. Products for the therapeutic area were added from 1949. The first to be launched was the plasma protein preparation “Biseko”, which is still marketed today. In 1986 the Biotest Serum-Institut GmbH was converted into Biotest AG. In 1987 the group went public with its common and preferred shares on the Frankfurt Stock Exchange. From 2007 to September 2018, the preferred shares were included in the SDAX selection index of Deutsche Börse. The company's shares are listed in the Prime Standard of the German stock exchange. The majority of the ordinary shares are held by Ogel GmbH, which is controlled by the Schleussner family.

Biotest has placed the strategic focus on concentrating on the core business with plasma proteins and biotherapeutics and expanding its position here through internationalization and research and development.

In January 2010, Biotest sold its business with reagents and devices for transfusion and transplantation diagnostics to Bio-Rad Laboratories, Inc., also based in Dreieich. In March 2011, the company agreed to sell the Microbiological Monitoring segment to Merck KGaA from Darmstadt, which im August 2011 took effect. At the end of 2012, Biotest received approval for the first immunoglobulin preparation (Bivigam (R)) for the American market. This was launched on the market at the beginning of 2013. In 2013 , a sales agreement was concluded with Merz Pharma GmbH & Co. KGaA , Frankfurt, for the Russian market and for the Greek business with Vianex s. a. To finance the Biotest Next Level production capacity doubling project at the Dreieich site, a capital increase was carried out in June 2013 with an issue volume of € 76 million and the placement of new preference shares on the market. In autumn 2013, a promissory note loan of over € 210 million was also placed. A clinical phase III study was also started in 2013 with Civacir (R), a preparation for reinfection prophylaxis against hepatitis C after liver transplantation. In 2014, a clinical study with the monoclonal antibody indatuximab ravtansine (BT-062) for the treatment of patients with solid tumors was started.

The construction work to expand capacity in Dreieich, which serves to double capacity and expand the portfolio, began in 2014. Overall, Biotest plans to invest around 300 million euros at the Dreieich site by 2020/21 and create 300 new jobs. With the “Biotest Next Level” investment program, Biotest will more than double the entire production capacity of the Biotest Group. The research and development projects focus on plasma proteins. Biotest is also actively pursuing opportunities to develop products in the area of ​​monoclonal antibodies together with partners.

In January 2018, Biotest was taken over by the Chinese investor Creat Group with a goodwill of 1.3 billion euros including debt. In order to obtain government approvals, Biotest sold its US operations to the Spanish pharmaceutical company Grifols .

Products and Markets

Biotest focuses on the Therapy , Plasma & Services and Other Segments business areas . The new Therapy segment includes the plasma proteins and monoclonal antibodies business , divided into three indication areas: hematology, clinical immunology and intensive care medicine. The Plasma & Services division includes plasma sales and contract manufacturing. The merchandise business and costs that cannot be allocated to the Therapy or Plasma & Services business areas are combined in Other Segments .

Therapy segment

This includes the strategic therapeutic areas of hematology, clinical immunology and intensive care medicine. These three therapeutic areas include plasma proteins and monoclonal antibodies .

Plasma proteins

Plasma proteins are obtained from human blood plasma ( plasma fractionation ). The production facilities are in Europe. Most of the plasma processed at Biotest comes from plasmapheresis . Biotest operates around 20 collection points of its own in Europe.

The plasma proteins can be divided into the main groups immunoglobulins , coagulation factors and albumins . Immunoglobulins are used for congenital or acquired diseases of the immune system as well as for serious infections, coagulation factors for blood clotting disorders ( hemophilia A and B ), albumins in emergency medicine, for example to stabilize the blood circulation in burns and serious injuries.

Special expertise, the company has at hyperimmunoglobulins that come in the prophylaxis and treatment of specific infectious diseases used, such as in the immune prevention of hepatitis B . In addition to immunoglobulins (polyspecific IVIG preparations), albumin and factor VIII preparations are among Biotest's most important product groups.

The core markets are Germany and the other member states of the European Union. In addition, the company is in Asian markets.

Monoclonal antibodies

Monoclonal antibodies are biotechnologically produced preparations. Biotest is currently developing two monoclonal antibodies.

  1. Monoclonal antibody indatuximab ravtansine (BT-062) for the treatment of multiple myeloma and other solid cancers such as triple-negative breast cancer and metastatic bladder cancer. BT-062 is a recombinant, chimerized, toxin-coupled therapeutic monoclonal antibody that binds to a target molecule on the surface of multiple myeloma cells and then destroys them.
  2. BT-063 monoclonal antibody for the treatment of systemic lupus erythematosus and other autoimmune diseases. BT-063 is a recombinant, humanized, therapeutic monoclonal antibody that specifically binds to an immune messenger substance and thereby neutralizes it.

Production and locations

The blood plasma required for Biotest is obtained by means of plasmapheresis in many of our own collection stations in Europe and obtained from selected suppliers.

The production ( fractionation ) of the plasma proteins takes place in the main plant in Dreieich.

Social Commitment

According to the company, there are collaborations with universities and colleges in Germany (for example in Frankfurt, Darmstadt, Mainz, Giessen and Wismar) for Bachelor, Master and PhD theses carried out in the company. Furthermore, Biotest states that, through donations, scientific activities in student training, for example, the Frankfurter Pharmazieschule e. V. and various patient organizations.

In addition, Biotest attaches great importance to the training of its own junior staff and the compatibility of family and career. In October 2014 Biotest received the “Certificate for the Promotion of Young Talent” from the Employment Agency for its exemplary commitment in training. In the summer of 2015, the company's own day-care center at the Dreieich location was opened for up to 80 children.

management

Board

  • Michael Ramroth, Chief Executive Officer and Chief Financial Officer
  • Georg Floß, Chief Operations Officer

Supervisory board

  • Rolf Hoffmann, Chairman of the Supervisory Board, Weggis, Switzerland
  • Tan Yang, Vice Chairman, Hong Kong, China
  • Jürgen Heilmann, Dreieich, Germany
  • Kerstin Birkhahn, Langen, Germany
  • Christine Kreidl, Regensburg, Germany
  • Cathrin Schleussner, Neu-Isenburg, Germany

Stock exchange

The company was converted into a public company in 1986; Since 1987 the shares (common and preferred shares) have been traded on the Prime Standard of the German Stock Exchange. From 2007 to September 2018, the preferred shares were included in the SDAX selection index .

Web links

Individual evidence

  1. ↑ Biotest website http://www.biotest.com/de/de/unternehmen/biotest_im_ueberblick/management/vorstand.cfm Retrieved on December 8, 2015
  2. ↑ a b Biotest website https://www.biotest.com/de/de/unternehmen/biotest_im_ueberblick/management/aufsichtsrat.cfm Retrieved on October 27, 2017
  3. ↑ a b Annual Report 2018. In: www.equitystory.com. Retrieved July 9, 2019 .
  4. ↑ Biotest exceeds already raised EBIT forecast , PM Biotest of February 26, 2020, accessed on March 3, 2020
  5. ↑ Company - Biotest at a glance , company website, accessed on March 3, 2020
  6. ↑ cf. Carl Adolf Schleussner , in: Internationales Biographisches Archiv 47/1959 of November 9, 1959, in the Munzinger Archive ( beginning of the article freely available)
  7. ↑ Boerse.de http://www.boerse.de/aktien/Biotest-Vz-Aktie/DE0005227235 Retrieved on December 8, 2015
  8. ↑ Wirecard rises: Founding member Commerzbank is thrown out of the Dax . In: FAZ.NET . ISSN  0174-4909 ( faz.net [accessed September 6, 2018]).
  9. ↑ Annual Report 2010, page 6 http://www.biotest.com/de/de/investor_relations/news_und_publikationen_/publikationen/geschaeftsberichte.cfm Retrieved on December 7, 2015
  10. ↑ Frankfurter Neue Presse http://sdp.fnp.de/lokales/kreise_of_gross-gerau/Eine-Investition-in-die-Zukunft;art688,1656352  ( page no longer available , search in web archives )  Info: The link was automatically saved as marked defective. Please check the link according to the instructions and then remove this notice. Retrieved December 8, 2015@1@ 2Template: Toter Link / sdp.fnp.de  
  11. ↑ Biotest website http://www.biotest.com/de/de/investor_relations/news_und_publikationen_/publikationen/quartalsberichte.cfm Retrieved on December 8, 2015
  12. ↑ Biotest creates 300 new jobs in Dreieich. In: Frankfurter Allgemeine Zeitung. January 28, 2019, accessed August 7, 2019 .
  13. ↑ Handelsblatt.de: Biotest takeover approved , January 19, 2018.
  14. ↑ Sale of business units brings Biotest high profits . In: https://www.op-online.de . August 14, 2018 ( op-online.de [accessed October 5, 2018]).
  15. ↑ Boersen-Zeitung.de https://www.boersen-zeitung.de/index.php?l=0&li=70&isin=DE0005227201&portrait=LANGPROFIL Retrieved on December 8, 2015
  16. ↑ Annual Report 2014 http://www.biotest.com/de/de/investor_relations/news_und_publikationen_/publikationen/geschaeftsberichte.cfm Retrieved on December 16, 2015
  17. ↑ Scientific engagement. Retrieved July 9, 2019 .
  18. ↑ OP-Online.de http://www.op-online.de/region/dreieich/biotest-langen-zertifikat-agentur-arbeit-4241975.html Retrieved on December 8, 2015
  19. ↑ OP-Online.de http://www.op-online.de/region/dreieich/dreieich-biotest-kita-sollen-auch-staedtische-plaetze-enthaben-5203255.html Retrieved on December 8, 2015
  20. ↑ Biotest promotes CFO Ramroth. In: finance-magazin. March 8, 2019, accessed August 7, 2019 .
  21. ↑ Wirecard rises: Founding member Commerzbank is thrown out of the Dax . In: FAZ.NET . ISSN  0174-4909 ( faz.net [accessed September 6, 2018]).